101 results match your criteria: "Atwal Clinic: Genomic & Personalized Medicine[Affiliation]"

Article Synopsis
  • Activating point mutations in the MET tyrosine kinase domain are identified as oncogenic drivers in various cancers, occurring in about 0.5% of cases, particularly in certain papillary renal cell carcinomas.
  • Specific mutations at positions H1094, L1195, F1200, D1228, Y1230, and M1250 were labeled as oncogenic or likely oncogenic based on genetic profiling.
  • Preclinical models and patient responses indicate that these mutations may enhance sensitivity to MET inhibitors, highlighting the potential for targeted precision treatments in oncology.
View Article and Find Full Text PDF

Pathogenic loss-of-function variants in BGN, an X-linked gene encoding biglycan, are associated with Meester-Loeys syndrome (MRLS), a thoracic aortic aneurysm/dissection syndrome. Since the initial publication of five probands in 2017, we have considerably expanded our MRLS cohort to a total of 18 probands (16 males and 2 females). Segregation analyses identified 36 additional BGN variant-harboring family members (9 males and 27 females).

View Article and Find Full Text PDF

We report on a study of next-generation sequencing in 257 patients undergoing investigations for cytopenias. We sequenced bone marrow aspirates using a target enrichment panel comprising 82 genes and used T cells from paired blood as a control. One hundred and sixty patients had idiopathic cytopenias, 81 had myeloid malignancies and 16 had lymphoid malignancies or other diagnoses.

View Article and Find Full Text PDF
Article Synopsis
  • The study introduces a new model called Genome-Derived-Diagnosis Ensemble (GDD-ENS) that uses genomic features from a large dataset of solid tumors (39,787 samples) to accurately classify tumor types.
  • GDD-ENS achieves 93% accuracy predicting 38 different cancer types, making it a promising alternative to traditional whole-genome sequencing methods that are less practical for clinical use.
  • The model not only classifies common tumor types but also aids in diagnosing rare cancers and incorporates patient-specific clinical information, enhancing its utility in real-time treatment decisions.
View Article and Find Full Text PDF
Article Synopsis
  • Cancer-testis (CT) genes are typically only found in the testis but can be expressed in tumors, making them potential targets for cancer immunotherapy.
  • A new bioinformatics pipeline was created to identify these CT genes and their expression levels in tumors, along with a scoring system to assess their relevance to clinical outcomes.
  • The study tested a synthetic peptide vaccine targeting CT genes in a mouse model of triple-negative breast cancer, demonstrating its potential to provoke strong immune responses and limit tumor growth.
View Article and Find Full Text PDF

Tumor type guides clinical treatment decisions in cancer, but histology-based diagnosis remains challenging. Genomic alterations are highly diagnostic of tumor type, and tumor type classifiers trained on genomic features have been explored, but the most accurate methods are not clinically feasible, relying on features derived from whole genome sequencing (WGS), or predicting across limited cancer types. We use genomic features from a dataset of 39,787 solid tumors sequenced using a clinical targeted cancer gene panel to develop Genome-Derived-Diagnosis Ensemble (GDD-ENS): a hyperparameter ensemble for classifying tumor type using deep neural networks.

View Article and Find Full Text PDF

Background: Cancer-testis (CT) genes are targets for tumor antigen-specific immunotherapy given that their expression is normally restricted to the immune-privileged testis in healthy individuals with aberrant expression in tumor tissues. While they represent targetable germ-tissue antigens and play important functional roles in tumorigenesis, there is currently no standardized approach for identifying clinically relevant CT genes. Optimized algorithms and validated methods for accurate prediction of reliable CT antigens with high immunogenicity are also lacking.

View Article and Find Full Text PDF

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.

Nature

May 2023

Baillie Gifford Pandemic Science Hub, Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.

Article Synopsis
  • Researchers analyzed genetic data from 24,202 critically ill COVID-19 cases, showing that host genetics can help identify effective immunomodulatory therapies.
  • They conducted a meta-analysis that revealed 49 significant genetic associations, including 16 new ones not previously reported.
  • Key findings include potential drug targets related to inflammation, immune response, and viral entry, which could lead to new treatment strategies for severe COVID-19 cases.
View Article and Find Full Text PDF

We report the case of a medically complex African American adult female with ornithine transcarbamylase (OTC) deficiency diagnosed after lifelong protein aversion and new onset of chronic vomiting and abdominal pain with intermittent lethargy and confusion. Symptomatology was crucial to diagnosis as genetic testing did not identify any pathogenic variants in ; however, the patient's diagnosis was delayed despite her having longstanding symptoms of a urea cycle disorder (UCD). Her symptoms improved after treatment with a modified protein-restricted diet, long-term nitrogen-scavenger therapy, and supplemental L-citrulline.

View Article and Find Full Text PDF

Clonal haematopoiesis involves the expansion of certain blood cell lineages and has been associated with ageing and adverse health outcomes. Here we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal haematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 24 loci (21 of which are novel) where germline genetic variation influences predisposition to CHIP, including missense variants in the lymphocytic antigen coding gene LY75, which are associated with reduced incidence of CHIP.

View Article and Find Full Text PDF

Body fat distribution is a major, heritable risk factor for cardiometabolic disease, independent of overall adiposity. Using exome-sequencing in 618,375 individuals (including 160,058 non-Europeans) from the UK, Sweden and Mexico, we identify 16 genes associated with fat distribution at exome-wide significance. We show 6-fold larger effect for fat-distribution associated rare coding variants compared with fine-mapped common alleles, enrichment for genes expressed in adipose tissue and causal genes for partial lipodystrophies, and evidence of sex-dimorphism.

View Article and Find Full Text PDF
Article Synopsis
  • * A systematic review of 54 studies analyzed over 17,500 cases to determine the prevalence of mismatch repair deficiency (MMRd) in OC, finding that 6.7% and 10.4% of cases tested positive for MMRd using immunohistochemistry and microsatellite instability analysis, respectively.
  • * The study indicates that a significant portion (up to 16%) of OC may respond to checkpoint inhibition therapy due to MMRd, but emphasizes the necessity for higher-quality research to validate these findings
View Article and Find Full Text PDF

Multiple familial diseases in a single patient often present with overlapping symptomatology that confers difficulty in delineating a clinical diagnosis. Pedigree analysis has been a long-standing practice in the field of medical genetics to discover familial diseases. In recent years, whole exome sequencing (WES) has proven to be a useful tool for aiding physicians in diagnosing and understanding disease etiology.

View Article and Find Full Text PDF

Background: The use of proactive genetic screening for disease prevention and early detection is not yet widespread. Professional practice guidelines from the American College of Medical Genetics and Genomics (ACMG) have encouraged reporting pathogenic variants that confer personal risk for actionable monogenic hereditary disorders, but only as secondary findings from exome or genome sequencing. The Centers for Disease Control and Prevention (CDC) recognizes the potential public health impact of three Tier 1 actionable disorders.

View Article and Find Full Text PDF

Given the expansion of genetics in medicine, there is a growing need to develop approaches to engage patients in understanding how genetics affects their health. Various qualitative methods have been applied to gain a deeper understanding of patient perspectives in topics related to genetics. Community dialogues (CD) are a bi-directional research method that invites community members to discuss a pertinent, challenging topic over the course of a multi-week period and the community members openly discuss their positions on the topic.

View Article and Find Full Text PDF

Sex Differences, Genetic and Environmental Influences on Dilated Cardiomyopathy.

J Clin Med

May 2021

Department of Cardiovascular Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.

Dilated cardiomyopathy (DCM) is characterized by dilatation of the left ventricle and impaired systolic function and is the second most common cause of heart failure after coronary heart disease. The etiology of DCM is diverse including genetic pathogenic variants, infection, inflammation, autoimmune diseases, exposure to chemicals/toxins as well as endocrine and neuromuscular causes. DCM is inherited in 20-50% of cases where more than 30 genes have been implicated in the development of DCM with pathogenic variants in (Titin) most frequently associated with disease.

View Article and Find Full Text PDF

T cell receptor (TCR) antigen-specific recognition is essential for the adaptive immune system. However, building a TCR-antigen interaction map has been challenging due to the staggering diversity of TCRs and antigens. Accordingly, highly multiplexed dextramer-TCR binding assays have been recently developed, but the utility of the ensuing large datasets is limited by the lack of robust computational methods for normalization and interpretation.

View Article and Find Full Text PDF

Background: With the increasing number of genomic sequencing studies, hundreds of genes have been implicated in neurodevelopmental disorders (NDDs). The rate of gene discovery far outpaces our understanding of genotype-phenotype correlations, with clinical characterization remaining a bottleneck for understanding NDDs. Most disease-associated Mendelian genes are members of gene families, and we hypothesize that those with related molecular function share clinical presentations.

View Article and Find Full Text PDF

The titular member of the MAX network of proteins, MYC-associated factor X (MAX), serves an important regulatory function in transcription of E-box genes associated with cell proliferation, differentiation, and apoptosis. Wild type MAX dimerizes with both MYC and MAD, both of which are members of the MAX network, and can promote or repress cell functions as needed. However, pathogenic variants in MAX are known to upset this balance, leading to uncontrolled oncogenic activity and disease phenotypes such as paragangliomas and pheochromocytomas.

View Article and Find Full Text PDF

Casein kinase 2-related disorders have been linked to pathogenic variants in CSNK2A1 and CSNK2B. CSNK2B-related disease is predominantly associated with neurodevelopmental abnormalities affecting cognition; however, the extent of the phenotype associated with CSNK2B pathogenic variants is yet to be fully explored. Here, we describe a patient with features suggestive of Poirier-Bienvenu neurodevelopmental syndrome, harboring a novel CSNK2B pathogenic variant.

View Article and Find Full Text PDF